Journal Article

Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

Edward V. Loftus, Xiaoyun Pan, Pete Zurawski, Parvez Mulani and Jingdong Chao

in Journal of Crohn's and Colitis

Published on behalf of European Crohn's and Colitis Organisation

Volume 5, issue 6, pages 550-554
Published in print December 2011 | ISSN: 1873-9946
Published online December 2011 | e-ISSN: 1876-4479 | DOI: https://dx.doi.org/10.1016/j.crohns.2011.05.005
Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

More Like This

Show all results sharing these subjects:

  • Medicine and Health
  • Clinical Medicine
  • Gastroenterology
  • Gastro-intestinal and Colorectal Surgery
  • Health, Illness, and Medicine

GO

Show Summary Details

Preview

Abstract

Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD).

Methods: Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1 year) were identified from a large specialty pharmacy database in the United States (March 2007–July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan–Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression.

Results: The overall adalimumab weekly dosing rate was 11.3% (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5%. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95% confidence intervals 0.33–0.7; p < 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast.

Conclusions: The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.

Keywords: Adalimumab; Crohn's disease; Weekly dosing; Predictors; Pharmacy claims data

Journal Article.  2430 words.  Illustrated.

Subjects: Medicine and Health ; Clinical Medicine ; Gastroenterology ; Gastro-intestinal and Colorectal Surgery ; Health, Illness, and Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.